𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Memantine in moderate to severe Alzheimer’s disease: an observational post-marketing study

✍ Scribed by Michael Rainer; A. Wuschitz; C. Jagsch; C. Erb; J.-J. Chirikdjian; H. A. M. Mucke

Publisher
Springer
Year
2011
Tongue
English
Weight
284 KB
Volume
118
Category
Article
ISSN
1435-1463

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Memantine enhances autonomy in moderate
Memantine enhances autonomy in moderate to severe Alzheimer's disease
✍ Benoît Rive; Martine Vercelletto; Florence Delamarre Damier; John Cochran; Cléme 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 101 KB

## Abstract ## Background Alzheimer's disease (AD) is the leading cause of dementia and its course renders patients functionally disabled. Memantine is the first drug to demonstrate a clinical benefit in the treatment of patients with moderately‐severe to severe AD. ## Objectives Our objective w

Tolerability of switching from donepezil
Tolerability of switching from donepezil to memantine treatment in patients with moderate to severe Alzheimer's disease
✍ Gunhild Waldemar; Maritta Hyvärinen; Mette Krog Josiassen; Alex Kørner; Heikki L 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 44 KB 👁 2 views

This study investigates the tolerability, safety and efficacy of abrupt or stepwise switching from donepezil to memantine treatment in patients with moderate-to-severe Alzheimer's disease (AD). Outpatients (Table 1), !50 years, with dementia of the Alzheimer's type (DSM-IV-TR), MMSE 18 and receiving

Improvement in behavioural symptoms in p
Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by memantine: a pooled data analysis
✍ S. Gauthier; H. Loft; J. Cummings 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 118 KB 👁 2 views

## Abstract ## Introduction Behavioural disturbances are a common and distressing aspect of Alzheimer's disease (AD). This pooled analysis evaluated the specific benefits of memantine on behavioural disturbances in patients with moderate to severe AD. ## Methods Data were pooled from six 24/28‐w

Safety and tolerability of once-daily ve
Safety and tolerability of once-daily versus twice-daily memantine: a randomised, double-blind study in moderate to severe Alzheimer's disease
✍ Roy W. Jones; Antony Bayer; Fraser Inglis; Andrew Barker; Ravinder Phul 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 97 KB 👁 1 views

## Abstract ## Objective To assess the safety and tolerability of three different dosing schedules of memantine in patients with moderate to severe Alzheimer's disease (AD). ## Method This 12‐week, randomised, double‐blind study, investigated three dosing schedules of memantine: OD1 (20 mg once